PairX Bio

Executive Summary

PairX Bio is a Singapore-based preclinical biotechnology company developing next-generation cancer-selective biologics. Leveraging proprietary technology licensed from Duke-NUS Medical School, the company targets tumor-specific cell-surface protein variants to create a pipeline of variant-specific therapeutics, including T-cell engagers, antibody-drug conjugates (ADCs), radioligands, and bispecific antibodies. This approach aims to achieve high efficacy with reduced off-target toxicity, potentially addressing a broad range of cancers. Founded in 2020, the company operates with a team of 50-200 employees and has not yet disclosed its total funding or valuation. PairX Bio's platform has the potential to overcome key limitations of conventional oncology biologics, such as on-target off-tumor toxicity and limited therapeutic windows. By focusing on unique protein variants present on tumor cells but absent on normal tissues, the company's candidates could offer superior selectivity and safety. While still in the preclinical stage, PairX Bio is positioned to attract partnership interest from larger pharmaceutical companies seeking novel targeted therapies. Near-term catalysts include advancement toward IND-enabling studies, potential licensing deals, and a Series A or B financing round to support pipeline progression.

Upcoming Catalysts (preview)

• 2027IND filing for lead variant-specific T-cell engager program30% success
• 2026Partnership or licensing agreement with a major pharma company40% success
• 2026Series A or B financing round70% success